rs80357783
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_007294.4(BRCA1):c.66_67insA(p.Glu23ArgfsTer18) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000137 in 1,460,784 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★★). Synonymous variant affecting the same amino acid position (i.e. L22L) has been classified as Likely benign.
Frequency
Consequence
NM_007294.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
BRCA1 | NM_007294.4 | c.66_67insA | p.Glu23ArgfsTer18 | frameshift_variant | 2/23 | ENST00000357654.9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
BRCA1 | ENST00000357654.9 | c.66_67insA | p.Glu23ArgfsTer18 | frameshift_variant | 2/23 | 1 | NM_007294.4 | P4 |
Frequencies
GnomAD3 genomes ? Cov.: 32
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1460784Hom.: 0 Cov.: 30 AF XY: 0.00000138 AC XY: 1AN XY: 726790
GnomAD4 genome ? Cov.: 32
ClinVar
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 1 Pathogenic:11
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Nov 08, 2023 | - - |
Pathogenic, no assertion criteria provided | clinical testing | BRCAlab, Lund University | Mar 02, 2020 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Breast Cancer Information Core (BIC) (BRCA1) | May 29, 2002 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | KCCC/NGS Laboratory, Kuwait Cancer Control Center | Aug 20, 2023 | This sequence change creates a premature translational stop signal (p.Glu23Argfs*18) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with breast and/or ovarian cancer (PMID: 8595420, 12181777, 16998791, 20189727, 24916970). This variant is also known as 185insA. ClinVar contains an entry for this variant (Variation ID: 37691) classified as pathogenic , reviewed by expert panel. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Jul 26, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge | Oct 02, 2015 | - - |
Pathogenic, reviewed by expert panel | curation | Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) | Apr 22, 2016 | Variant allele predicted to encode a truncated non-functional protein. - |
Pathogenic, criteria provided, single submitter | clinical testing | Department of Molecular Diagnostics, Institute of Oncology Ljubljana | Apr 02, 2020 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Sharing Clinical Reports Project (SCRP) | Jul 17, 2013 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Endocrinology Laboratory, Christian Medical College | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Department of Medical Genetics, Oslo University Hospital | Jul 01, 2015 | - - |
not provided Pathogenic:10Uncertain:1
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneKor MSA | Jan 01, 2020 | This sequence change inserts one nucleotide in exon 2 of BRCA1 mRNA (c.66dupA), causing a frameshift at codon 23 and the creation of a premature translation stop signal 18 amino acid residues later. This is expected to result in an absent or disrupted protein product. Truncating variants in BRCA1 are known to be pathogenic. This variant is also known as 185insA in the literature and it has been reported in the literature in individuals and families with breast and/or ovarian cancer (PMID: 8595420, 20189727, 24916970, 16998791). The mutation database ClinVar contains entries for this variant (Variation ID: 37691). - |
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jul 11, 2023 | This variant alters the translational reading frame of the BRCA1 mRNA and causes the premature termination of BRCA1 protein synthesis. In the published literature, this variant has been reported in individuals with breast cancer (PMID: 35918668 (2022), 35220195 (2022), 34290354 (2021), 32733560 (2020), 29470806 (2018), 29176636 (2018)) and endometrial cancer (PMID: 31492746 (2019)). This variant has not been reported in large, multi-ethnic general populations (Genome Aggregation Database, http://gnomad.broadinstitute.org). Based on the available information, this variant is classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Sep 05, 2014 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Feb 15, 2022 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 30, 2023 | Observed in individuals with personal or family history consistent with pathogenic variants in this gene (Kroiss et al., 2005; Rashid et al., 2006; Thirthagiri et al., 2008; Noel et al., 2010; Ginsburg et al., 2011; Peixoto et al., 2014; Heramb et al., 2018); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Not observed in large population cohorts (gnomAD); Also known as 185dupA or 185insA; This variant is associated with the following publications: (PMID: 8595420, 27157322, 10952777, 29339979, 29752822, 16287141, 30078507, 31492746, 20189727, 26187060, 22798144, 25103822, 23374397, 24916970, 20950396, 18627636, 12181777, 28179634, 27257965, 16998791, 29907814, 29116469, 29433453, 28993434, 8807330, 30702160, 27553291, 29470806, 28176296, 31528241, 32733560, 32341426, 29176636, 31742824, 31825140, 30787465, 11597388, 35220195, 34290354, 32211327, 15026808, 35264596, 35377489, 31892343) - |
Hereditary breast ovarian cancer syndrome Pathogenic:5
Pathogenic, no assertion criteria provided | research | Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto | Jan 31, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | Jul 02, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | National Health Laboratory Service, Universitas Academic Hospital and University of the Free State | Nov 16, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 14, 2016 | Variant summary: The BRCA1 c.66dupA (p.Glu23Asnfs) variant results in a premature termination codon, predicted to cause a truncated or absent BRCA1 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g. p.Gln60X, p.Tyr101X, p.Glu143X, etc.). This variant is absent in 120930 control chromosomes from ExAC. The variant is a recurrent pathogenic variant found in several HBOC patients/families and in individuals undergoing BRCA1/2 testing. In addition, several clinical diagnostic laboratories/reputable databases have classified this variant as pathogenic. Taken together, this variant is classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Dec 07, 2023 | This sequence change creates a premature translational stop signal (p.Glu23Argfs*18) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with breast and/or ovarian cancer (PMID: 8595420, 12181777, 16998791, 20189727, 24916970). This variant is also known as 185insA. ClinVar contains an entry for this variant (Variation ID: 37691). For these reasons, this variant has been classified as Pathogenic. - |
Familial cancer of breast Pathogenic:3
Pathogenic, no assertion criteria provided | clinical testing | Bioscientia Institut fuer Medizinische Diagnostik GmbH, Sonic Healthcare | Nov 16, 2018 | - - |
Pathogenic, no assertion criteria provided | literature only | Center for Precision Medicine, Meizhou People's Hospital | - | - - |
Pathogenic, criteria provided, single submitter | research | A.C.Camargo Cancer Center / LGBM, A.C.Camargo Cancer Center | Jan 30, 2019 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 21, 2021 | The c.66dupA pathogenic mutation, located in coding exon 1 of the BRCA1 gene, results from a duplication of one nucleotide at position 66, causing a translational frameshift with a predicted alternate stop codon (p.E23Rfs*18). This mutation has been described in numerous breast and ovarian cancer patients and families (Couch FJ and Weber BL. Hum. Mutat. 1996;8:8-18; Rashid MU et al. Int. J. Cancer. 2006 Dec;119:2832–39; Kang E et al. Breast Cancer Res. Treat. 2015 May;151:157-68; Bujassoum SM et al. J. Cancer Sci. Ther. 2017;9(2):358-64). Of note, this alteration is also designated as 185insA in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Pathogenic, criteria provided, single submitter | curation | Sema4, Sema4 | Dec 20, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Oct 10, 2023 | This variant inserts 1 nucleotide in exon 2 of the BRCA1 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in at least 10 Individuals affected with breast and ovarian cancer and in a breast cancer case-control meta-analysis in 3 cases and 1 unaffected individual (PMID: 8595420, 11606101, 12181777, 18627636, 20189727, 20950396, 27257965, 28993434, 29152070, 29470806, 33471991, 35918668; Leiden Open Variation Database DB-ID BRCA1_001098), and in suspected hereditary breast and ovarian cancer families (PMID: 10952777, 16683254, 16998791, 21559243, 24916970, 25863477, 29176636, 29339979, 29907814). This variant also has been reported in an individual affected with melanoma (PMID: 29433453). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. - |
Breast neoplasm Pathogenic:1
Pathogenic, criteria provided, single submitter | research | Laboratory of Molecular Diagnosis of Cancer, West China Hospital, Sichuan University | Nov 01, 2015 | - - |
Ovarian neoplasm Pathogenic:1
Pathogenic, no assertion criteria provided | research | German Consortium for Hereditary Breast and Ovarian Cancer, University Hospital Cologne | Dec 01, 2018 | - - |
Breast carcinoma Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Medical Genetics Laboratory, Umraniye Training and Research Hospital, University of Health Sciences | Aug 08, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at